Grading of chemotherapy-induced peripheral neuropathy (Q33977591)

30 July 2017

1 reference

title

Grading of chemotherapy-induced peripheral neuropathy (English)

1 reference

Chemotherapy-induced peripheral neuropathy

30 July 2017

1 reference

1 reference

T J Postma

1

1 reference

PubMed ID

10907941

30 July 2017

J J Heimans

series ordinal

2

1 reference

30 July 2017

1 May 2000

1 reference

30 July 2017

1 reference

30 July 2017

11

1 reference

30 July 2017

5

1 reference

30 July 2017

509-513

1 reference

Neurotrophic factors in peripheral neuropathies: pharmacological strategies

30 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Comprehensive criteria for assessing therapy-induced toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Paclitaxel-induced neuropathy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Limitations of quantitative sensory testing when patients are biased toward a bad outcome

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Peripheral sensory neuropathy and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Prospective nerve conduction studies in cisplatin therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Taxol produces a predominantly sensory neuropathy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Cisplatin neuropathy: clinical course and neurophysiological findings

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Examination of distal involvement in cisplatin-induced neuropathy in man

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Who should measure quality of life, the doctor or the patient?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

A critical appraisal of the quality of quality-of-life measurements

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Outcome research in neurology: Incorporating health-related quality of life

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Cancer-specific quality of life questionnaires: the state of the art in Europe

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008345613594

7 January 2021

Identifiers

DOI

10.1023/A:1008345613594

1 reference

30 July 2017

1 reference

PubMed ID

10907941